Drug Profile

ARC 520

Alternative Names: ARC-520

Latest Information Update: 09 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arrowhead Research Corporation
Developer Arrowhead Pharmaceuticals
Class Antivirals; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hepatitis B

Most Recent Events

09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics
11 Apr 2018 Updated efficacy data from the phase II Heparc-2001 trial in Hepatitis B presented at the International Liver Congress (ILC-2018)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com